Cullinan Therapeutics (CGEM) Initial Form 3 Shows Zero Beneficial Ownership

Rhea-AI Filing Summary

Cullinan Therapeutics (CGEM) Form 3: Andrew R. Allen filed an initial Section 16 statement on behalf of himself as a director of Cullinan Therapeutics reporting the event date 08/07/2025. The filing states that no securities are beneficially owned by the reporting person. The form was signed by an attorney-in-fact, Jacquelyn Sumer, on 08/08/2025. No derivative or non-derivative holdings are listed.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Allen Andrew R

(Last) (First) (Middle)

C/O CULLINAN THERAPEUTICS, INC.

ONE MAIN STREET, SUITE 1350

(Street)

CAMBRIDGE MA 02142

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
08/07/2025

3. Issuer Name and Ticker or Trading Symbol
Cullinan Therapeutics, Inc. [ CGEM ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

Exhibit 24.1 - Power of Attorney

No securities are beneficially owned.

	/s/ Jacquelyn Sumer, Attorney-in-Fact	08/08/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did the Form 3 filed for Cullinan Therapeutics (CGEM) report?

The Form 3 reports that Andrew R. Allen, a director, filed an initial beneficial ownership statement and no securities are beneficially owned.

Who is the reporting person on the Form 3 for CGEM?

The reporting person is Andrew R. Allen, listed as a director of Cullinan Therapeutics.

What is the date of the event requiring the Form 3 filing for CGEM?

The date of the event requiring the statement is 08/07/2025.

Was the Form 3 signed and when?

The Form 3 was signed by an attorney-in-fact, Jacquelyn Sumer, on 08/08/2025.

Does the Form 3 list any derivative or non-derivative securities for CGEM?

No. The filing explicitly states no securities are beneficially owned and lists no derivative or non-derivative holdings.